MOTS-c vs Thymosin Alpha-1
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →Thymosin Alpha-1
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.
Full details →Side-by-Side Comparison
| Aspect | MOTS-c | Thymosin Alpha-1 |
|---|---|---|
| Dose Range | 5 mg–10 mg | 1.6 mg–3.2 mg |
| Frequency | Less than daily | Less than daily |
| Cycle Length | 8–12 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. | Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes. |
| Typical Dosage | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. | Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary. |
| Administration | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. | Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols. |
| Side Effects | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. | Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue. |
| Best For |
Key Differences
Unique to MOTS-c:
Unique to Thymosin Alpha-1:
Key Studies
MOTS-c
- MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.
Free radical biology & medicine, 2026
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.
Redox biology, 2025
- MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?
Cardiovascular drugs and therapy, 2025
Thymosin Alpha-1
- Aging and Thymosin Alpha-1.
International journal of molecular sciences, 2025
- Phenotypic drug discovery: a case for thymosin alpha-1.
Frontiers in medicine, 2024
- The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
Inflammopharmacology, 2023
Ready to Learn More?
Looking for trusted sources?